Drug pricing policy in Hungary

Zoltán Vincze, Romána Zelkó, Ágnes Mészáros

Research output: Contribution to journalReview article


Besides the political, economical and social changes that occurred in the nineties, the structure and the financing of the health care systems were also thoroughly altered in Hungary. Before the nineties the price levels of medicines were kept depressed artificially. Only a minimal part of the costs of research, development and promotion was calculated in the prices of products. The purpose of the present study was to illustrate the characteristics of the transitional period and the present status of the Hungarian Health System. The authors also described the two big groups of the subsidizing systems existing in Hungary, those of the percent based and value-limited systems.

Original languageEnglish
Pages (from-to)189-204
Number of pages16
JournalJournal of Pharmaceutical Finance, Economics and Policy
Issue number3
Publication statusPublished - Dec 1 2003



  • Hungarian health system
  • National Health Insurance Office
  • Percent based and value-limited subsidizing systems

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Health Policy

Cite this